Form 4: Centessa Pharmaceuticals General Counsel Executes Option and Sells Shares Under Pre-Planned Trading Plan

Centessa Pharmaceuticals plc's General Counsel, Iqbal J. Hussain, exercised stock options and subsequently sold 6,000 ordinary shares for a profit, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Iqbal J. Hussain, General Counsel of Centessa Pharmaceuticals plc, executed a transaction on July 15, 2025.
• Hussain acquired 6,000 ordinary shares by exercising a share option at a price of $5.84 per share.
• Immediately following the exercise, Hussain disposed of 6,000 ordinary shares through a sale on the open market.
• The shares were sold at a weighted average price of $14.9278, with individual transactions ranging from $14.78 to $15.11.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Hussain on September 14, 2024.
• After these transactions, Hussain directly beneficially owns 105,386 ordinary shares.
• Hussain also directly holds 285,559 share options (right to buy) with an exercise price of $5.84, which began vesting on February 19, 2022, and expire on February 19, 2031.
• An additional 5,500 ordinary shares are indirectly beneficially owned by Hussain's spouse.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While it's an insider sale, it's an exercise-and-sell transaction for profit, executed under a pre-planned 10b5-1 plan, which is generally viewed as less concerning than an unannounced, opportunistic sale of existing shares. It reflects the executive monetizing vested compensation.

Positives

• The General Counsel realized a significant profit from the option exercise and subsequent sale, with shares acquired at $5.84 and sold at an average of $14.9278.
• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than an opportunistic one, which can mitigate concerns about insider selling.

Negatives

• The sale of shares by a key executive, even if pre-planned, reduces their direct equity stake in the company, which some investors might interpret as a slight reduction in management's direct alignment with shareholder interests.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.

Industry Context

This is a routine insider transaction filing (Form 4) for a publicly traded pharmaceutical company. Such filings are common and reflect executive compensation and personal financial planning, rather than broader industry trends or competitive positioning.

Corporate Governance

Related Party Transactions

• Iqbal J. Hussain indirectly beneficially owns 5,500 ordinary shares through his spouse.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-planned program, which typically has minimal direct impact on shareholders beyond the transparency of executive compensation monetization.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The remaining 75% of the share options will continue to vest in 36 monthly installments on the first day of each month, following the initial 25% vesting on February 19, 2022.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Sale, Option Exercise, Iqbal Hussain, General Counsel, 10b5-1 Plan